Tufts-Center for the Evaluation of Value and Risk in Health (CEVR) is now accepting submissions for the annual CEVR Cost-Effectiveness Analysis (CEA) ...
Read more2022 CEA Registry Remote Summer Fellowship What is CEVR and the CEA Registry? CEVR is a leading research center on issues pertaining to value, cost-ef...
Read moreThe CEA Registry reached a major milestone this month: 10,000 articles! This honor goes to a study published in Feb 2021 by Dr. Dan Su and colleagues ...
Read moreChambers JD, Margaretos NM, Enright DE, Wang R, Ye X. Is an Orphan Drug's Cost-Effectiveness Associated with US Health Plan Coverage Restrictiveness? Pharmacoeconomics. 2021 Oct 26. doi: 10.1007/s40273-021-01096-5
Madison C. Silver, Peter J. Neumann, Siyu Ma, David D. Kim, Joshua T. Cohen, Mawuli Nyaku, Craig Roberts, Anushua Sinha, Daniel A. Ollendorf, Frequency and impact of the inclusion of broader measures of value in economic evaluations of vaccines, Vaccine, 2021,
Margaretos NM, Patel AM, Panzer AD, Lai RC, Whiteley J, Chambers JD. Variation in access to hemophilia A treatments in the United States. J Med Econ. 2021 Jan-Dec;24(1):1143-1148
Lin P, Neumann PJ. Valuing Alzheimer Disease Therapies—Considering Costs and Benefits Beyond the Patient. JAMA Netw Open. 2021;4(10):e2131913. doi:10.1001/jamanetworkopen.2021.31913
Margaretos NM, Panzer AD, Lai RC, Sanon M, Michalopoulos E, Redmond A, Moghadam R, Chambers JD. Variation in health plan coverage of ESAs for anemia due to chronic kidney disease, J Manag Care Spec Pharm, 2021 Sep;27(9):1221-1229
Kim DD, Griauzde DH, Richardson CR, Fendrick AM. Clinically-driven payment and benefit design to improve health equity: The case of obesity prevention and treatment. Health Affairs Blog. September 10, 2021.
D’Cruz B, Graff JS, Panzer AD, Chambers JD. Limited role of patient input in specialty drug coverage policies. Journal of Managed Care & Specialty Pharmacy 2021;27(8):1067–76.
Kim DD, Basu A. How does cost-effectiveness analysis inform health care decisions? AMA J Ethics. 2021;23(8):E639-647.
Lin PJ, Daly AT, Olchanski N, Cohen JT, Neumann PJ, Faul JD, Fillit HM, Freund KM. Dementia diagnosis disparities by race and ethnicity. Medical Care 2021;59(8):679–86.
Chambers J, Lin P, Tunis SR, Neumann PJ, Medicare ‘Coverage With Evidence Development’ For Aducanumab? How Might It Work? Health Affairs, June 30, 2021.
Do LA, Synnott PG, Ma S, Ollendorf DA. Bridging the gap: aligning economic research with disease burden. BMJ Global Health 2021;6(6).
Neumann PJ, Ollendorf DA, Cohen JT. Value‐based drug pricing in the Biden era: Opportunities and prospects. Health Services Research 2021.
Ollendorf DA, Synnott PG, Neumann PJ. "External reference pricing: The drug-pricing reform America needs?," The Commonwealth Fund Issues Brief, May 27, 2021.
Chambers JD, Neumann PJ. "A next frontier in health care transparency: payer drug coverage policy," Health Affairs Blog, April 7, 2021.
Kim DD, Do LA, Daly AT, Wong JB, Chambers JD, Ollendorf DA, Neumann PJ. An Evidence Review of Low-Value Care Recommendations: Inconsistency and Lack of Economic Evidence Considered. J Gen Intern Med. 2021 Feb 23.
Our team of experienced, dedicated researchers is led by health economists Peter Neumann and Josh Cohen. Together we produce cutting-edge health care cost-effectiveness research.
Meet the CEVR TeamOur comprehensive databases provide the information individuals and organizations need to analyze the benefits, risks, and costs of strategies to improve health and health care.
The CEA Registry is a comprehensive database of 9,080 cost-utility analyses on a wide variety of diseases and treatments.
View RegistryThe GH CEA Registry is the first comprehensive database to compile articles utilizing the “cost-per-DALY averted” metric to measure the efficacy of health interventions.
View RegistryThe Specialty Drug Evidence and Coverage (SPEC) Database is a new data resource developed with the goal of providing an empirical basis to commercial payer specialty drug coverage.
View Database